pitavastatin (itavastatin)

Also Known As:

itavastatin; nisvastatin; (E,3R,5S)-7-(2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoic acid; NK 104; NK-104; P 872441; P-872441; itavastatin calcium; pitavastatin calcium; pitavastatin lactone

Networked: 559 relevant articles (90 outcomes, 203 trials/studies)

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 207
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 148
      - pitavastatin: 559

Experts

1.	Daida, Hiroyuki: 20 articles (08/2023 - 06/2004)
2.	Kimura, Takeshi: 18 articles (08/2023 - 12/2006)
3.	Ozaki, Yukio: 18 articles (01/2023 - 12/2006)
4.	Matsuzaki, Masunori: 17 articles (01/2023 - 11/2006)
5.	Miyauchi, Katsumi: 17 articles (01/2023 - 06/2004)
6.	Saito, Yasushi: 17 articles (01/2023 - 01/2002)
7.	Hiro, Takafumi: 16 articles (01/2023 - 12/2006)
8.	Nakagawa, Yoshihisa: 16 articles (01/2023 - 12/2006)
9.	Egashira, Kensuke: 14 articles (05/2022 - 08/2010)
10.	Nakano, Kaku: 13 articles (05/2022 - 08/2010)

Related Diseases

1.	Hypercholesterolemia 04/10/2012 - "To evaluate the safety and efficacy of pitavastatin in patients with hypercholesterolemia in China under conditions of extensive usage. " 04/10/2012 - "[Safety and efficacy of pitavastatin in patients with hypercholesterolemia: a multicenter study]." 04/01/2008 - "One year of pitavastatin treatment improved not only carotid arterial stiffness but also regional LV systolic and diastolic function in patients with hypercholesterolemia and preserved LVEF. " 05/01/2011 - "The Livalo Effectiveness and Safety (LIVES) study was an observational study to examine the efficacy and safety of pitavastatin, a newly developed drug, in approximately 20,000 Japanese patients with hypercholesterolemia. " 05/01/2011 - "Efficacy and safety of pitavastatin in Japanese patients with hypercholesterolemia: LIVES study and subanalysis."
2.	Dyslipidemias (Dyslipidemia) 01/01/2021 - "This was a multicentre (four private hospitals) prospective cohort study to analyze data on the use of pitavastatin for dyslipidemia in adult outpatients in Abu Dhabi and Dubai, United Arab Emirates. " 10/02/2020 - "A 47-year-old male was admitted to our hospital with dyslipidemia, he had been taking pitavastatin 2 mg/day for 2 months. " 11/01/2019 - "She was taking pitavastatin for dyslipidemia. " 01/01/2019 - "Pitavastatin is a more commonly prescribed medication for the treatment of dyslipidemia. " 01/01/2016 - "Therefore, it seems that pitavastatin should preferentially be considered in the treatment of dyslipidemia in diabetic patients or at risk of developing diabetes."
3.	Inflammation (Inflammations) 02/01/2022 - "Therefore, findings of the present study may help to elucidate the mechanisms underlying the effects of pitavastatin on vascular endothelial cell inflammation and injury." 04/02/2015 - "Pitavastatin not only improved the atherosis as measured by IMT and cIBS values but also attenuated inflammation of plaques as measured by max SUV at the same site. " 02/01/2022 - "Collectively, results from the present study demonstrated that treatment with pitavastatin preserves MAPK7 expression to alleviate Ang II-induced vascular endothelial cell inflammation and injury. " 02/01/2022 - "The present study aimed to evaluate the effects of pitavastatin on HUVEC injury and inflammation. " 01/01/2015 - "Our study provides in vivo evidence that pitavastatin reduces inflammation within atherosclerotic lesions in CRD mice."
4.	Hyperlipidemias (Hyperlipidemia) 08/01/2015 - "To assess the safety and efficacy of pitavastatin in children and adolescents with hyperlipidemia. " 12/01/2020 - "This study was designed to administer 1, 2, or 4 mg pitavastatin to patients with hyperlipidemia at the age of 20 or older for at least 8 weeks. " 05/01/2018 - "In the European study, 106 children and adolescents with high risk hyperlipidemia (103 heterozygous FH), aged 10.6±2.9 years, were randomized to 12-week double-blind treatment with 1, 2 or 4 mg/day pitavastatin or placebo; 84 of these patients and 29 new patients participated in a 52-week open-label extension study. " 01/01/2017 - "Pitavastatin is approved for the treatment of hyperlipidemia and has also been shown to inhibit stem cell proliferation in preliminary in vitro studies. " 08/01/2015 - "A total of 106 children and adolescents with hyperlipidemia, ages 6 to 17 years, were enrolled in a 12-week randomized, double-blind, placebo-controlled study and randomly assigned to pitavastatin 1 mg, 2 mg, 4 mg, or placebo. "
5.	Neoplasms (Cancer) 12/01/2019 - "Collectively, the results lay a foundation for further investigation of pitavastatin's therapeutic efficacy in tumor-induced bone loss, as well as VOC-based diagnosis of tumor progression and treatment efficacy.-Wang, L., Wang, Y., Chen, A., Teli, M., Kondo, R., Jalali, A., Fan, Y., Liu, S., Zhao, X., Siegel, A., Minami, K., Agarwal, M., Li, B.-Y., Yokota, H. " 01/01/2016 - "Moreover, pitavastatin decreased the tumor growth and improved the survival of tumor-bearing mice. " 03/01/2022 - "These data identified foods that patients could eat to potentially improve the outcome of clinical trials of pitavastatin in cancer." 01/01/2021 - "The Anti-Cancer Effect of Pitavastatin May Be a Drug-Specific Effect: Subgroup Analysis of the TOHO-LIP Study." 08/08/2017 - "Studies with pitavastatin in primary patient derived tumor cells and established PDA lines, revealed dose dependent growth inhibition. "

Related Drugs and Biologics

1.	Lipids
2.	Atorvastatin (Lipitor)
3.	oxidized low density lipoprotein
4.	Rosuvastatin Calcium (Crestor)
5.	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)
6.	Pravastatin (Pravachol)
7.	Simvastatin (Zocor)
8.	Ezetimibe (Zetia)
9.	Glucose (Dextrose)
10.	Biomarkers (Surrogate Marker)

Related Therapies and Procedures

1.	Therapeutics
2.	Neoadjuvant Therapy
3.	Renal Dialysis (Hemodialysis)
4.	Chemoprevention
5.	Immunotherapy